Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents

November 1, 2021

Schauer; Buddhe; Colyer; et al.

The Journal of Pediatrics

A retrospective review of electronic medical records was performed. Inclusion criteria were patients under 18 years of age presenting with severe chest pain and signs of myopericarditis within one week of receiving the second dose of the Pfizer COVID-19 vaccine between April 1, 2021 and June 21, 2021. 13 patients with myopericarditis were found, with a median age of 15 years (range, 12-17 years). Most of the patients were men (n = 12; 92%). The median time to presentation was 3 days (range, 2-4 days). All patients presented with severe and persistent chest pain of sudden onset that was not exacerbated by movement or activity.

Schauer J, Buddhe S, Colyer J, et al. Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents. The Journal of Pediatrics 2021; 238: 317–20.

Partners